Case report: Area of focus of management of severe pityriasis rubra pilaris by dose optimization of adalimumab biosimilar in combination with acitretin and montelukast

Case report: Area of focus of management of severe pityriasis rubra pilaris by dose optimization of adalimumab biosimilar in combination with acitretin and montelukast

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder characterized by hyperkeratotic follicular papules, orange-red scaling plaques with islands of sparing and palmoplantar keratoderma. While spontaneous resolution occurs in some cases, treatment can be challenging for others. The use...

Full description

Bibliographic Details
Main Authors: Kristine Heidemeyer, S. Morteza Seyed Jafari, Lena Farnina, Simon Bossart, Laurence Feldmeyer, Nikhil Yawalkar
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Medicine
Subjects:
pityriasis rubra pilaris
adalimumab
biosimilar
dose-optimization
phospholipase A2
montelukast
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1295777/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1295777/full

Similar Items